A tablet developed in Melbourne that “melts away” cancer cells has been approved for use in the United States. The U.S. Food and Drug Administration announced on Tuesday that Venetoclax was approved for prescription outside of human trials for patients with chronic lymphotic leukemia. Venetoclax, which overwhelms the BCL-2 protein that is vital to cancer cell survival, was developed in Melbourne in the 1980s after researchers at the Walter and Eliza Hall Institute of Medical Research discovered the importance of BCL-2. 80 of 116 participants in a human trial of the drug in Melbourne have displayed a positive response.
http://news.xinhuanet.com/english/2016-08/23/c_135626129.htm
